Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Avenue Therapeutics, Inc. ATXI

Healthcare  —  Biotechnology
0.50 0.14 38.89% as of 24 Sep
Market cap
$680.0K
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Avenue Therapeutics, Inc. (ATXI) Business Profile

Updated before January 2025

Company Overview

Avenue Therapeutics, Inc. (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and chronic pain. Founded in 2015, the company is headquartered in New York City, New York. Avenue Therapeutics operates as a subsidiary of Fortress Biotech, Inc., a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical products. The company is led by a team of experienced executives, including its CEO, Dr. Lindsay A. Rosenwald, who has a strong background in the pharmaceutical and biotechnology industries.

Core Business Segments

Avenue Therapeutics specializes in the development of pain management therapies, with a primary focus on acute post-operative pain. The company’s flagship product is:

  • IV Tramadol: A proprietary intravenous formulation of tramadol, a widely used pain medication. IV Tramadol is designed to address the unmet need for non-opioid and non-NSAID (nonsteroidal anti-inflammatory drug) pain management options in the hospital setting. It is particularly targeted at patients who require effective pain relief but are at risk of complications from traditional opioids or NSAIDs.

The company’s pipeline is focused on advancing IV Tramadol through regulatory approvals and exploring additional indications for its use.

Business Model

Avenue Therapeutics operates on a business model that combines pharmaceutical development with strategic partnerships. The company’s primary revenue generation strategy revolves around the successful commercialization of IV Tramadol. This includes:

  1. Regulatory Approvals: Securing FDA and other global regulatory approvals for IV Tramadol.
  2. Licensing and Partnerships: Collaborating with other pharmaceutical companies to distribute and market its products in various regions.
  3. Market Expansion: Targeting hospitals and healthcare providers to integrate IV Tramadol into their pain management protocols.

By focusing on a single, high-potential product, Avenue Therapeutics aims to establish itself as a leader in the acute pain management market.

Strategic Direction

Avenue Therapeutics has outlined a clear strategic direction to ensure its growth and sustainability:

  1. Regulatory Milestones: The company is actively working to address the FDA’s concerns regarding IV Tramadol and secure final approval for its use in the United States.
  2. Global Expansion: Avenue Therapeutics plans to explore international markets for IV Tramadol, particularly in regions with high demand for non-opioid pain management solutions.
  3. Pipeline Development: While IV Tramadol remains the primary focus, the company is exploring opportunities to expand its product pipeline with additional pain management therapies.
  4. Sustainability Goals: Avenue Therapeutics is committed to reducing the reliance on traditional opioids, thereby contributing to the global effort to combat the opioid crisis.

Competitive Landscape

Avenue Therapeutics operates in a highly competitive pharmaceutical market. Key competitors include:

  • Mallinckrodt Pharmaceuticals: A global specialty pharmaceutical company with a strong presence in pain management.
  • Pacira BioSciences, Inc.: Known for its non-opioid pain management solutions, including Exparel.
  • Heron Therapeutics, Inc.: Focused on developing novel pain management therapies, including non-opioid alternatives.
  • Collegium Pharmaceutical, Inc.: Specializes in pain management products, including extended-release formulations of opioids.

Avenue Therapeutics differentiates itself by focusing on IV Tramadol, a unique product that addresses a specific gap in the market.

Risk Factors

Like any pharmaceutical company, Avenue Therapeutics faces several risks:

  1. Regulatory Challenges: Delays or rejections in obtaining FDA approval for IV Tramadol could significantly impact the company’s growth prospects.
  2. Market Dependence: The company’s reliance on a single product, IV Tramadol, makes it vulnerable to market fluctuations and competitive pressures.
  3. Supply Chain Disruptions: Any disruptions in the supply chain for raw materials or manufacturing could delay product availability.
  4. Competition: The presence of established players in the pain management market poses a constant threat to Avenue Therapeutics’ market share.
  5. Financial Constraints: As a smaller pharmaceutical company, Avenue Therapeutics may face challenges in securing funding for its operations and pipeline development.

Recent Developments

Avenue Therapeutics has made significant progress in advancing IV Tramadol:

  • Regulatory Updates: The company has been actively engaging with the FDA to address concerns raised during the approval process for IV Tramadol. Recent developments indicate progress toward resolving these issues.
  • Clinical Trials: Avenue Therapeutics has completed multiple Phase 3 clinical trials demonstrating the safety and efficacy of IV Tramadol for acute pain management.
  • Partnerships: The company has entered into strategic partnerships to support the commercialization and distribution of IV Tramadol upon approval.
  • Global Developments: The ongoing opioid crisis has increased demand for non-opioid pain management solutions, creating a favorable market environment for IV Tramadol.

Investment Considerations

Investors considering Avenue Therapeutics should weigh the following strengths and risks:

Strengths:

  • Innovative Product: IV Tramadol addresses a critical need for non-opioid pain management solutions.
  • Market Potential: The global pain management market is expected to grow significantly, providing ample opportunities for revenue generation.
  • Experienced Leadership: The company is led by a team with extensive experience in the pharmaceutical industry.

Risks:

  • Regulatory Uncertainty: Delays in FDA approval could impact the company’s timeline for commercialization.
  • Single Product Focus: Dependence on IV Tramadol makes the company vulnerable to market and regulatory risks.
  • Financial Challenges: Limited financial resources may constrain the company’s ability to execute its growth strategy.

Conclusion

Avenue Therapeutics, Inc. is a promising player in the pharmaceutical industry, with a clear focus on addressing the unmet need for non-opioid pain management solutions. While the company faces challenges related to regulatory approvals and market competition, its innovative product, IV Tramadol, positions it well for future growth. With a strategic focus on global expansion and pipeline development, Avenue Therapeutics has the potential to become a leader in the acute pain management market.